Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis. Ruxolitinib will remain a main stay in the treatment of MPN patients due to its effective therapeutic benefits. However, there have been instan...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	myeloproliferative neoplasm JAK2-V617F ruxolitinib resistance Hsp90 inhibitior type I JAK2 inhibition
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1430833/full

Similar Items

A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance
by: Sivahari Prasad Gorantla, et al.
Published: (2024-02-01)

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
by: Tobias Idor Boklund, et al.
Published: (2024-05-01)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
by: Blum S, et al.
Published: (2016-09-01)

Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia Areata
by: Yotaro Tamai, et al.
Published: (2022-05-01)

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
by: Sophia S. Lee, et al.
Published: (2021-08-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
by: Eylem Eliaçık, et al.
Published: (2015-05-01)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
by: Nikolas von Bubnoff, et al.
Published: (2018-11-01)

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01)

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
by: Emmanouil Spanoudakis, et al.
Published: (2018-10-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
by: Jeffrey S. Smith, MD, PhD, et al.
Published: (2023-08-01)

Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms
by: Meike Kaehler, et al.
Published: (2024-07-01)

Recent progress of JAK inhibitors for hematological disorders
by: Keita Kirito
Published: (2023-07-01)

Case Report and Literature Review of Acute Spontaneous Intraspinal Epidural Hematoma (SSEH) Secondary to Myeloproliferative Disease
by: Liu Q, et al.
Published: (2024-05-01)

Evaluation of JAK2V617F Mutation Patients with Non-CML Myeloproliferative Neoplasms by ARMS-PCR
by: K Alimoghaddam, et al.
Published: (2008-09-01)

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
by: Kanwaljeet Singh, et al.
Published: (2018-01-01)

Gender and age characteristics of <I>JAK2</I> V617F mutation allelic burden and <I>CALR</I> and <I>MPL</I> driver mutations detection during primary examination of patients with suspected myeloproliferative neoplasms
by: I. A. Olkhovskiy, et al.
Published: (2024-12-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
by: M. Cem Ar, et al.
Published: (2012-08-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
by: Popova-Labachevska M, et al.
Published: (2019-12-01)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
by: Michael Stephan Bader, et al.
Published: (2022-01-01)

Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review
by: Jona F. Houthuys, et al.
Published: (2022-12-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Mohsen Razavi, et al.
Published: (2011-10-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Akram Asghari, et al.
Published: (2011-12-01)

Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study
by: Hrvoje Holik, et al.
Published: (2023-06-01)

Ruxolitinib Alleviates Uveitis Caused by <i>Salmonella typhimurium</i> Endotoxin
by: Lin Du, et al.
Published: (2021-07-01)

Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis
by: Elif Gülsüm Ümit, et al.
Published: (2024-09-01)

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
by: Anniina T. Virtanen, et al.
Published: (2023-01-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Mehrdad Payande, et al.
Published: (2011-06-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Farhad Shaveisi Zadeh, et al.
Published: (2011-04-01)

IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients
by: Ahmed Rushdi Abdullah
Published: (2022-04-01)

Primary and secondary myelofibrosis: ophthalmological manifestations at onset and during therapy
by: O. Yu. Vinogradova, et al.
Published: (2025-03-01)

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms
by: Guangshuai Teng, et al.
Published: (2025-07-01)

The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
by: Deesha Desai, BS, et al.
Published: (2024-08-01)

Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review
by: Ioana Butnariu, et al.
Published: (2023-12-01)

Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression
by: İldeniz USLU-BIÇAK, et al.
Published: (2025-05-01)

Ruxolitinib cream for the treatment of granuloma annulare
by: Austin J. Piontkowski, BS, et al.
Published: (2024-08-01)

Association of JAK2 Haplotype GGCC_46/1 with the Response to Onco-Drug in MPNs Patients Positive for JAK2V617F Mutation
by: Michela Perrone, et al.
Published: (2024-09-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)